The twelve-month cost

Twelve months is where the advertised price and the real price finally diverge far enough to see.

Across the programmes where the monthly figure genuinely includes the medication, a year of compounded tirzepatide runs from about $1,500 at Trimi to $5,388 at Henry Meds. Same class of medication at both ends.

The board over a year

Across our board a year of compounded tirzepatide runs from roughly $1,500 to $5,388 — the same class of medication, a spread of nearly $3,900. Almost none of that gap is the drug. It is fee structure, dose tiering and introductory rates that lapsed in month two.

The full-year table

Annual plans: the real trade

The lowest rates in this market nearly all require a twelve-month commitment. The discount is genuine — often $600 or more a year — but you are lending a company a year of payments for a treatment you may not tolerate. A reasonable approach is to start month-to-month, get through two dose increases, then switch to annual once you know it suits you.

Brand-name, for comparison

Through LillyDirect self-pay, single-dose Zepbound vials at 5 mg, 7.5 mg and 10 mg have been listed at $499/month, with lower starting doses nearer $299-$349.

Through NovoCare, Wegovy has been offered at $199/month for the first two fills through 31 December 2026, then $349/month for 0.25-2.4 mg doses. The oral form is listed between $149 and $299/month by dose.

Those are FDA-approved products. The gap against compounded programmes has narrowed a great deal since manufacturers opened self-pay channels, which is worth knowing before assuming compounded is automatically cheaper — we work through it in what you actually pay.